About Avidity Biosciences, Inc. - Common Stock (RNA)
Avidity Biosciences Inc is a biotechnology company focused on developing innovative therapies that leverage its proprietary AOC platform, which stands for antibody-oligonucleotide conjugates. This platform aims to deliver therapeutic oligonucleotides directly to specific cells using antibodies, thereby enhancing the precision and effectiveness of treatments for various diseases, including genetic disorders and cancer. The company's research is centered around improving the delivery and efficacy of RNA-based therapies, with the goal of transforming the treatment landscape for patients through targeted and personalized medicine. Read More
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Avidity Biosciences, Inc. (NASDAQ: RNA) to Novartis for $72.00 per share in cash is fair to Avidity shareholders.
U.S. companies have struck more than $80 billion worth of deals in the past 24 hours, in the latest sign that mergers and acquisitions (M&A) are picking up after the tariff-induced cool-off earlier this year.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Avidity Biosciences, Inc. (NasdaqGM: RNA) to Novartis AG. Under the terms of the proposed transaction, shareholders of Avidity will receive $72.00 in cash for each share of Avidity that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
BALA CYNWYD, Pa., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.
The session on Monday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
